PhRMA’s Post

In the biopharmaceutical industry, change is always around. Navigating change requires more than implementing new technologies or processes—it requires a focus on the people who will be impacted by the change. Certified change pracitioners, Melissa Mauriber and Jenny Chandler, CSP, author our blog on how you can best navigate change. Read the blog: https://hubs.la/Q02C853t0 #ClinicalResearch #ClinicalTrials #ChangeManagement

Increasing the diversity of clinical trial participants has become a goal for many organizations in the biopharmaceutical space; however, improving patient diversity is easier said than done. In our latest Patient Diversity report, identifying and recruiting new sites or using sites in different countries/regions/cities is the tactic most often used among survey respondents trying to improve patient diversity. This tactic is also considered the most impactful. Explore our new Patient Diversity report here: https://lnkd.in/eHGEK3Jc #patientdiversity #clinicaltrials #marketresearch #clinicaldevelopment

Your work in life science is as complex as it gets?     Out of 10,000 potential drug candidates, only one will make it to market, often taking more than a decade. This reflects the level of complexity of biopharmaceutical research and development.    At Sartorius, we understand the challenges and opportunities that our partners face during research, development, and production. And we’re committed to working alongside them, assisting in navigating the twist and turns of the scientific landscape.    We’re in this together. We simplify the complex to make your work easier.     Let’s simplify together at https://lnkd.in/ed_dEEUi    #SimplifyingProgress #LifeSciences #bioprocessing #InThisTogether 

Biopharmaceutical Research & Development (R&D) stands at an inflection point— with the limiting factor for innovation no longer being science or funding but the speed at which clinical trials can be completed. Beyond proud to have contributed to this article, where my McKinsey colleagues explore the barriers to improving R&D productivity. Read it here: https://lnkd.in/eXeq7-x2

Don’t bite the hand that feeds you. The hypocrisy McCullough Foundation here is laughable. Peter McCullough received more money from Pharma that he calls now the "Biopharmaceutical Complex" than what he made as a doctor from 2016-2022. He received $1,622,321 in payments from the pharmaceutical industry, 6,300% more than the average US physician as demonstrated in https://lnkd.in/eQSN4Wnu As for "Generating fear to increase uptake.", you should be reminded that McCullough relentlessly generates fear about spike proteins. And such only to push a solution he says he has ! His company sells (for $64.99 a bottle) an herbal supplement called "Spike Support", claimed to "dissolve spike proteins inside your body", something that basically does not exist per se but from which he makes money. And tons of it. For $299.99, McCullough's company will sell you "the medications you need for the next pandemic" (ivermectin, azithromycin & amoxicillin) which, if purchased separately at CVS, would cost a total of $43.09. A mark-up well beyond acceptable, especially that it just does not work…

🌐 Dive into the transformative impact of #AI on drug discovery with 1859! The biopharmaceutical industry is on the brink of a revolution, but the key lies in overcoming the scarcity of high-quality training data. Join us in this insightful webinar as we unveil groundbreaking strategies to accelerate drug discovery through our innovative approach. 📌 Register here: https://buff.ly/40LctLS #DataAnalytics #Datasets #ArtificialIntelligence #DataScience #DataAutomation #SmallMoleculeDrugDiscovery

Single-use systems and solutions offer global biopharmaceutical manufacturing the speed, efficiency, and reliability needed to produce breakthrough treatments and therapies. But in an increasingly high-demand environment, supply assurance is critical as manufacturers focus on innovation. Watch the video to learn more about how Avantor’s single-use solutions support overcoming complex challenges. #AvantorSetsScienceInMotion

Advanced analytics allow biopharmaceutical companies to efficiently analyze trial data, quicken decisions, and hasten therapy delivery. Discover more here.  https://bit.ly/46rFTAC #DataAnalytics #HealthTech #MedicalAffairs #DigitalHealth #ClinicalTrials

How can quality organizations embrace a patient-centric approach to drive value? To find out where the industry stands on ‘patient-centered quality’, we surveyed and assessed biopharmaceutical and medtech companies’ current approach to quality. Explore our findings.

By leveraging advanced data analytics, biopharmaceutical companies can effectively interpret vast clinical trial data, expedite decision-making, and accelerate the delivery of new therapies to patients. Learn more about how advanced analytics are transforming clinical trials here - https://bit.ly/46rFTAC #ClinicalTrials #DataAnalytics #BioPharma #MedicalAffairs #HealthcareData